For instance, tebentafusp, an FDA-approved TCR-ScFv fusion molecule, showed overall survival benefit to UM by targeting gp100 on tumor cells and CD3 on T cells and eventually redirecting T cells toward tumor cells [128]. The gene discussed is PMEL; the disease is neoplasm.